Borderline tumours of the ovary: A 37-year experience at a tertiary referral centre
- PMID: 39428825
- DOI: 10.1111/ajo.13876
Borderline tumours of the ovary: A 37-year experience at a tertiary referral centre
Abstract
Introduction: Borderline ovarian tumours (BOT) are a common epithelial ovarian tumours. Typically diagnosed at an early stage with a good prognosis, many BOT are treated conservatively. Recurrence is common. This update to our last audit in 1997 represents one of the largest audits of BOT to date.
Materials and methods: All patients with BOT managed at 'the hospital' from 1984 to 2021 were included. Expert pathology review was available.
Results: There were 549 cases included. The recurrence rate was 5% (n = 29/549) with 1.4% (n = 8/549) undergoing malignant transformation. Three of the eight women who recurred as cancer died from their disease. Frozen section was predictive of histologic diagnosis in 92% (n = 55/60) of serous tumours (SBOT), but only 62% (n = 54/87) of mucinous tumours (MBOT). In MBOT where the appendix appeared normal intra-operatively, it was histologically benign in all cases (n = 63). In SBOT, the recurrence rate was 5/23 (22%), 12/52 (23%), 1/29 (3%) and 3% (P = <0.01) for unilateral cystectomy, unilateral oophorectomy ± cystectomy, bilateral oophorectomy, and bilateral oophorectomy with hysterectomy, respectively, as index procedure. In MBOT this correlated to 2/20 (10%), 3/93 (3%), 0 and 1/58 (2%), respectively.
Discussion: This study describes important information correlating first surgical procedure and fertility-sparing surgery to recurrence and malignant transformation. For all BOT subtypes, fertility-preserving surgery increased the risk of recurrence and hysterectomy was not superior to removal of both ovaries. In MBOT, frozen section is of limited utility and the macroscopically normal appendix is very unlikely to be anything but benign, if MBOT is the true histologic diagnosis.
Keywords: appendicectomy; borderline ovarian tumours; fertility‐preserving surgery; malignant transformation; restaging surgery; surgical staging.
© 2024 Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
References
REFERENCES
-
- Anne Kathrin Höhn CEB, Hiller GGR, May D et al. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 2021; 81: 1145–1153.
-
- Colombo N, Sessa C, Bois AD et al. ESMO‐ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 2019; 29: 728–760.
-
- Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2017; 41: 49–59.
-
- du Bois A, Trillsch F, Mahner S et al. Management of borderline ovarian tumors. Ann Oncol 2016; 27(Suppl 1): i20–i21.
-
- Trillsch F, Mahner S, Woelber L et al. Age‐dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub‐analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol 2014; 25: 1320–1327.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical